Phage Consultants is a company specializing in bacteriophage problems troubleshooting and prevention. It was founded in 2007 based on many years of experience in this field of its founder. Company, among other phage prevention- and troubleshooting-related activities, provides RCB, WCB and MCB testing for the presence of virulent phages and inducible prophages, also in strict anaerobes. Most probably, we have the greatest experience in this field on the whole global market. | PHAGE CONSULTANTS specializes in prevention and troubleshooting of phage contamination problems in various production and laboratory setups through a variety of services. We offer phage detection and identification services, facility audits and initial assessments, consultations, personnel training, advice on bioprocess optimization and SOP improvement, and new facility development. We also offer fast and reliable routine or as-required testing of incoming bacterial strains and cell banks for the presence of both lytic phages and prophages – a necessary tool in phage prevention. With these services, Phage Consultants can help you avoid phage contaminations and recover quickly from contaminations that have already occurred. | We are a company specializing in phage contamination troubleshooting and prevention with 18 years of experience on the market. We helped to solve over 200 cases of phage contamination in production facilities and research labs. Among the other activities, we provide RCB, WCB and MCB testing for the presence of virulent phages and inducible prophages, also in very unusual hosts like strict anaerobes. Such tests are very important in order to provide smooth production process and to avoid any problems with ready product. We also provide contract research in any field of phage use, which may be also the modification and fine tuning of microbiome. If our activity is anyhow interesting for you, I would be delighted to schedule a meeting with your representative.
Novotech
Novotech is a globally recognized full-service clinical research organization (CRO) and scientific advisory company that provides biotech and small- to mid-sized pharma companies an accelerated path to market since 1997. With a global footprint spanning 30+ offices across the Asia-Pacific region, North America, and Europe, and partnerships with 5,000+ trial sites, Novotech offers unparalleled access to key clinical trial destinations and diverse patient populations. Novotech leverages its therapeutic and regulatory expertise, client-centric service model, local market insights, and advanced analytical tools to expedite patient recruitment, enhance trial efficiencies, and bring life-changing therapies to market faster. This work has been recognized by awards such as the Frost & Sullivan CRO Company of the Year, which Novotech has received for 19 consecutive years.
NONA BIOSCIENCES
Nona Biosciences is a biotechnology company offering integrated solutions for antibody discovery and development. Leveraging our proprietary Harbour Mice® platforms, which generate fully human H2L2 and heavy chain-only antibodies (HCAbs), we enable a broad range of therapeutic formats with high developability and flexibility. Nona’s HCAbs are the first and only clinically validated, fully human heavy chain-only antibodies on the market, offering advantages such as low immunogenicity, high solubility, and strong biophysical properties. Our H2L2 Open Access Platform enables rapid entry into discovery, while Modalities-on-Demand™ provides tailored support for bispecifics, TCEs, and other next-generation modalities including ADCs, CAR-T, and mRNA-based therapies. With capabilities spanning immunization, screening, engineering, and IND-enabling services, Nona empowers partners to move efficiently from idea to IND with flexibility and confidence. Our platforms have supported more than 300 discovery programs and over 19 partner INDs through a variety of collaboration models. | Nona Biosciences is a Boston-based Biotechnology company specialized in fully human antibody discovery. Harbour Mice®, our proprietary technology, are fully human transgenic mice platforms for either conventional fully human antibody (H2L2) or heavy chain only (HCAb) antibody discovery, engineering, and development. The HCAb platform produces human Vh single domain antibodies, providing multiple advantages for bispecific and multispecific antibody engineering | Nona Biosciences is a Boston-based Biotech company specialized in fully human therapeutic antibody technology. Our proprietary Harbour Mice® technology are fully human transgenic mice platforms for either conventional fully human antibody (H2L2) or heavy chain only (HCAb) antibody discovery, engineering, and development. The HCAb platform is fully optimized and clinically validated with global patented protection. Nona Biosciences can provide comprehensive antibody discovery services from Idea to IND, which range from Beacon® Single B Cell Cloning, display technology to functional screening, characterization, in vivo efficacy assessment, antibody engineering, and CMC for clinical candidate generation. | Nona Biosciences is a biotechnology company offering integrated solutions for antibody discovery and development. Leveraging our proprietary Harbour Mice® platforms, which generate fully human H2L2 and heavy chain-only antibodies (HCAbs), we enable a broad range of therapeutic formats with high developability and flexibility. Nona’s HCAbs are the first and only clinically validated, fully human heavy chain-only antibodies on the market, offering advantages such as low immunogenicity, high solubility, and strong biophysical properties. Our H2L2 Open Access Platform enables rapid entry into discovery, while Modalities-on-Demand™ provides tailored support for bispecifics, TCEs, and other next-generation modalities including ADCs, CAR-T, and mRNA-based therapies. With capabilities spanning immunization, screening, engineering, and IND-enabling services, Nona empowers partners to move efficiently from idea to IND with flexibility and confidence. Our platforms have supported more than 300 discovery programs and over 19 partner INDs through a variety of collaboration models. Nona Biosciences is a biotechnology company offering integrated solutions for antibody discovery and development. Leveraging our proprietary Harbour Mice® platforms, which generate fully human H2L2 and heavy chain-only antibodies (HCAbs), we enable a broad range of therapeutic formats with high developability and flexibility. Nona’s HCAbs are the first and only clinically validated, fully human heavy chain-only antibodies on the market, offering advantages such as low immunogenicity, high solubility, and strong biophysical properties. Our H2L2 Open Access Platform enables rapid entry into discovery, while Modalities-on-Demand™ provides tailored support for bispecifics, TCEs, and other next-generation modalities including ADCs, CAR-T, and mRNA-based therapies. With capabilities spanning immunization, screening, engineering, and IND-enabling services, Nona empowers partners to move efficiently from idea to IND with flexibility and confidence. Our platforms have supported more than 300 discovery programs and over 19 partner INDs through a variety of collaboration models.
NJ Bio
NJ Bio, Inc. is a CRO/CDMO specializing in integrated chemistry and biology services for ADCs and other complex bioconjugates. We offer comprehensive solutions spanning discovery, development, characterization, optimization, and bioanalysis, complemented by robust in vitro and in vivo capabilities to support translational decision-making. We provide toxicology, pharmacology, PK, and immunology services to support safety assessment, efficacy profiling, and translational development of ADC and bioconjugate programs. Our expertise in synthetic chemistry, bioconjugation, linker design, and bioanalytical capabilities, ensure seamless support across the entire drug development process and help accelerate ADC programs to become front-line treatments for cancer patients. | NJ Bio, Inc. is a CRO/CDMO that provides high-quality integrated chemistry and biology services to clients mostly from the biotech and pharma sectors. Main service areas include antibody-drug conjugates, bioconjugation, and multistep organic synthesis. The company is headquartered in Princeton, New Jersey, with additional chemistry facilities in Bristol, Pennsylvania. NJ Bio’s facility in Princeton, NJ, occupies ~ 80,000 sq ft of laboratory and office space, with specialized laboratory suites for highly potent compound synthesis, bioconjugation, bioassays, and analytical studies. The facility is very well equipped with instrumentation required for ADC- and bioconjugation-related work. | NJ Bio, Inc. is a CRO/CDMO specializing in integrated chemistry and biology services for ADCs. We offer comprehensive solutions for ADC development, characterization, optimization, and bioanalysis. Our expertise in synthetic chemistry, bioconjugation, linker design, and bioanalytical capabilities, ensure seamless support across the entire drug development process and help accelerate ADC programs to become front-line treatments for cancer patients. | NJ Bio, Inc., is a CRO that provides high-quality integrated chemistry and biology services for ADCs, bioconjugates and nucleic acid-based therapeutics. We strive to be a beacon of excellence in contract research, development and manufacturing by providing cutting-edge biopharmaceutical and advanced chemistry services. Backed by deep expertise in bioconjugation & chemical synthesis, we add value to targeted therapeutic programs through integrated services in conjugation, process development, characterization, and bioanalysis of complex molecules.
NEUROPHET
NEUROPHET Inc., Seoul, Republic of Korea, with expertise in neuroscience. We have been focusing on developing and providing innovative medical solutions for helping patients suffering from neurological diseases. To achieve the mission, we have applied state-of-the-art AI technologies to our expertise in neuroimaging, brain modeling and neuromodulation. We are conducting research in imaging-based biomarkers for Alzheimer’s disease (AD), which will be valuable tool for clinical trials (surrogate biomarker for drug response and disease progression) and companion diagnostics for AD therapeutics and furthermore, global standardization for AD staging and diagnostics. Neurophet provides medical-grade solutions approved by international regulatory bodies. | Neurophet Inc. develops advanced AI-powered neuroimaging solutions to enhance the diagnosis, monitoring, and treatment planning of neurological disorders. Its flagship products—AQUA AD, AQUA, and SCALE PET—deliver precise, quantitative insights into brain atrophy, lesion dynamics, and imaging biomarkers, including those associated with amyloid-targeted therapeutics (ATT) and amyloid-related imaging abnormalities (ARIA), through MRI and PET imaging. | Neurophet is a specialized company developing AI-powered brain imaging analysis solutions and therapeutic medical devices, covering the full cycle of neurological care — from MRI and PET analysis to wearable brain stimulation devices. We support medical institutions with AI-based imaging for diagnosis and treatment monitoring, and provide standardized central imaging services for global pharmaceutical clinical trials through our Imaging Core Lab (ICL). From the clinical frontline to global clinical trials, Neurophet is advancing as a global leader in neurological imaging analysis.
Neuro-Sys
Neuro-Sys is a globally recognized, research-driven CRO specializing in advanced in vitro and in vivo models for neurodegenerative disease drug development. Our expertise in pharmacology and drug discovery allows us to offer unparalleled insights into compound mechanisms. Our studies empower clients to make informed decisions at every stage of drug development, building a cohesive narrative around compound efficacy and safety. Backed by a team of skilled neuropharmacologists, we are committed to delivering precise, reliable data through innovative technology and tailored research platforms. This commitment, combined with superior customer service, ensures efficiency and drives our clients’ success. | Neuro-Sys is a globally recognized, research-driven CRO specializing in advanced in vitro and in vivo models for neurodegenerative disease drug discovery. Our studies empower clients to make informed decisions at every stage of drug development, building a cohesive narrative around compound efficacy and safety. Backed by a team of experts, we are committed to delivering precise, reliable data through innovative technology and custom study designs. This commitment, combined with superior customer service, ensures efficiency and drives our clients’ success.
NanoTag Biotechnologies GmbH
Custom-tailored single-domain antibody solutions We provide high-quality single-domain antibodies (sdAbs) to advance research and biomedicine. From tailored sdAb discovery and innovative technologies to tools for immunofluorescence, super-resolution microscopy, and affinity purification, our solutions ensure reliability and precision. With custom-engineered nanobodies and protein production services, we empower you to tackle complex scientific challenges with confidence. Unlock the full potential of sdAbs with NanoTag Biotechnologies.
Mexico Pavilion (MEX BIO)
MEX BIO Pavilion – BIO International Convention 2026 The MEX BIO Pavilion represents Mexico’s coordinated national presence at the BIO International Convention, the world’s leading global event for biotechnology and life sciences. Since 2022, Mexico has maintained a continuous and growing participation at BIO through a national pavilion, reflecting the strategic importance of the life sciences sector for the country and the sustained collaboration between industry, government, academia, and innovation stakeholders. MEX BIO serves as a platform for international engagement, business development, and ecosystem positioning, bringing together Mexican pharmaceutical and biotechnology companies, CROs and CDMOs, startups, research institutions, clusters, and public agencies. Over the past four editions, more than 50 Mexican organizations have participated, positioning Mexico as a key life sciences hub in Latin America and a reliable partner for global collaboration. The Pavilion is designed to go beyond a traditional exhibition space. Through a curated program of activities—including MEX BIO Day, MEX BIO Talks, MEX BIO Walks, and high-level institutional engagements—the Pavilion facilitates targeted meetings, strategic dialogues, and direct interaction with international partners, investors, and decision-makers. A dedicated digital platform and ecosystem wall further enhance visibility and extend engagement before, during, and after the Convention. Mexico’s presence at BIO reflects the country’s commitment to innovation, advanced manufacturing, regulatory dialogue, and international cooperation in life sciences. The MEX BIO Pavilion offers global stakeholders a unique entry point to explore Mexico’s capabilities, connect with its innovation ecosystem, and identify opportunities for collaboration, investment, and market access in one of the region’s most dynamic life sciences environments.